Cefmenoxime (Cefmax)

A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

Also Known As:

Cefmax; Abbott-50192; Cefmenoxime Hydrochloride; Cefmenoxime Hydrochloride (2:1); SCE-1365; Abbott 50192; Abbott50192; Hydrochloride, Cefmenoxime; SCE 1365; SCE1365; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-

Networked: 129 relevant articles (17 outcomes, 20 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kawakami, Hideaki: 2 articles (01/2020 - 07/2019)
2.	Mochizuki, Kiyofumi: 2 articles (01/2020 - 07/2019)
3.	Murata, Kazuhiro: 2 articles (01/2020 - 07/2019)
4.	Ozawa, Kenji: 2 articles (01/2020 - 07/2019)
5.	Ohkusu, Kiyofumi: 1 article (01/2020)
6.	Asano, Yuko: 1 article (07/2019)
7.	Mikamo, Hiroshige: 1 article (07/2019)
8.	Nakayama, Asami: 1 article (07/2019)
9.	Takahashi, Shunsuke: 1 article (07/2019)
10.	Yamada, Hiroki: 1 article (07/2019)

Related Diseases

1.	Infections 03/01/1983 - "In the cefmenoxime group, all except one urethral infection were eradicated. " 01/01/1985 - "On the whole, this study showed a significant placental transfer of cefmenoxime, achieving therapeutic concentrations required against microorganisms responsible for obstetrical infections." 05/01/1984 - "On the whole, this study showed a significant placental transfer of cefmenoxime, achieving therapeutic concentrations required against microorganisms responsible for obstetrical infections." 10/01/1982 - "[Laboratory and clinical studies of cefmenoxime in pediatric infections]." 02/01/1995 - "The 7-[2-(2-aminothiazol-4-yl)-2-(Z)-cyclopentyloxyimino]acet ami do derivative 9g provided good subcutaneous efficacy and exhibited more potent activity than cefmenoxime (11) against the systemic infection with S. "
2.	Meningitis 02/01/1986 - "Efficacy of cefmenoxime in experimental group B streptococcal bacteraemia and meningitis." 05/01/1985 - "[Cefmenoxime diffusion into cerebrospinal fluid during human purulent meningitis]." 09/01/1985 - "Efficacy of cefmenoxime in experimental Escherichia coli bacteremia and meningitis." 02/01/1986 - "In-vivo studies using experimental bacteraemia and meningitis in newborn rats revealed that despite similar drug levels, cefmenoxime had significantly greater bactericidal titres in blood at 6-7 h after administration and bacterial clearance from blood was significantly faster with cefmenoxime than with penicillin G at the end of one day of treatment. " 01/01/1985 - "Two grams of cefmenoxime (CMX) was administered by one-shot intravenous injection to the patients in normal pressure hydrocephalus without meningitis, and the transference of CMX into the cerebrospinal fluid (CSF) from blood was investigated. "
3.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/1990 - "Schentag et al studied patients with lower respiratory tract infection treated with cefmenoxime alone and found a significant relationship between time greater than MIC & time to clearance of the pathogen from cultures of the tracheobronchial tree. " 09/01/1988 - "[Study on the effectiveness and safety of cefmenoxime in the treatment of respiratory tract infections. " 11/01/1986 - "[Laboratory and clinical studies on cefmenoxime in respiratory tract infections]." 01/01/1983 - "This bacteriological and pharmacokinetic study was therefore performed in order to evaluate the potency of cefmenoxime in the treatment of respiratory infections. " 09/01/1988 - "The effectiveness and safety of cefmenoxime (CMX) in the treatment of respiratory tract infections were evaluated, mainly in relation to the appearance of hemorrhagic tendency. "
4.	Urinary Tract Infections (Urinary Tract Infection) 01/01/1985 - "The efficacy of cefmenoxime (CMX), which is a third generation, beta-lactamase-resistant cephem with a broad antibacterial spectrum, was examined in 43 patients with chronic complicated urinary tract infections. " 06/01/1985 - "Cefmenoxime (CMX) was intravenously administered to 106 patients with complicated urinary tract infection at a daily dose of 2-4 g for 5 days. " 06/01/1985 - "[Clinical experience with cefmenoxime (CMX) in complicated urinary tract infections]." 02/01/1985 - "[Clinical evaluation of cefmenoxime (CMX) for complicated urinary tract infection]." 01/01/1985 - "[Clinical evaluation of cefmenoxime in chronic complicated urinary tract infection]."
5.	Keratitis 01/01/2017 - "The combination of corneal scraping and instillation of cefmenoxime antibiotic ophthalmic solution was considered useful for the treatment of Kocuria keratitis. " 07/01/2019 - "The use of duo-therapy with a combination of fluoroquinolone and cefmenoxime should be considered in cases nonresponsive to monotherapy, such as keratitis and bleb-associated infections. " 07/01/2013 - "To study the in vitro interaction of fluoroquinolones such as levofloxacin (LVFX), gatifloxacin (GFLX), or moxifloxacin (MFLX) in combination with tobramycin (TOB) or cefmenoxime (CMX) against clinical isolates of bacteria from keratitis. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	Cefotiam
3.	Cephalosporins (Cephalosporin Antibiotics)
4.	Cefotaxime (Kendrick)
5.	Ceftriaxone (Ceftriaxon)
6.	Cefsulodin
7.	Penicillins (Penicillin)
8.	Penicillin G (Benzylpenicillin)
9.	Amikacin (A.M.K)
10.	Moxalactam (Latamoxef)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Gynecologic Surgical Procedures (Gynecologic Surgery)
3.	Therapeutics
4.	Intravenous Infusions
5.	Intravenous Administration